Previous Close | 6.76 |
Open | 6.93 |
Bid | 8.01 x 100 |
Ask | 8.33 x 100 |
Day's Range | 6.91 - 8.29 |
52 Week Range | 5.92 - 18.65 |
Volume | |
Avg. Volume | 97,185 |
Market Cap | 149.538M |
Beta (5Y Monthly) | 0.27 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.43 |
Earnings Date | May 06, 2024 - May 10, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 22.00 |
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Highly Synergistic Antiproliferative Activity in EGFR-resistant Cells in Combination with Osimertinib, the Active Ingredient in TagrissoTM Single Agent Antiproliferative Activity in Cells Resistant to Alectinib, the Active Ingredient in AlecensaTM Fort Lee, NJ, April 08, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) today recapped poster highlights from the 2024 American Association for Cancer Research (AACR) conference demonstrating highly synergistic antiproliferative activity
Whilst it may not be a huge deal, we thought it was good to see that the Nuvectis Pharma, Inc. ( NASDAQ:NVCT...